[go: up one dir, main page]

MA30485B1 - Aminothiazoles et leurs utilisations - Google Patents

Aminothiazoles et leurs utilisations

Info

Publication number
MA30485B1
MA30485B1 MA31428A MA31428A MA30485B1 MA 30485 B1 MA30485 B1 MA 30485B1 MA 31428 A MA31428 A MA 31428A MA 31428 A MA31428 A MA 31428A MA 30485 B1 MA30485 B1 MA 30485B1
Authority
MA
Morocco
Prior art keywords
aminothiazoles
amelioration
diseases
prevention
useful
Prior art date
Application number
MA31428A
Other languages
English (en)
Inventor
Matthew J Lamarche
Simon Bushell
Michael A Patane
Lewis Whitehead
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30485(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30485B1 publication Critical patent/MA30485B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention décrit des composés organiques qui sont utiles dans le traitement, la prévention et/ou l'amélioration de maladies.
MA31428A 2006-05-31 2008-12-01 Aminothiazoles et leurs utilisations MA30485B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80969306P 2006-05-31 2006-05-31

Publications (1)

Publication Number Publication Date
MA30485B1 true MA30485B1 (fr) 2009-06-01

Family

ID=38645676

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31428A MA30485B1 (fr) 2006-05-31 2008-12-01 Aminothiazoles et leurs utilisations

Country Status (31)

Country Link
US (2) US7851439B2 (fr)
EP (2) EP2322536A3 (fr)
JP (1) JP5351014B2 (fr)
KR (1) KR101061658B1 (fr)
CN (2) CN101454337A (fr)
AR (1) AR060977A1 (fr)
AU (1) AU2007255025B2 (fr)
BR (1) BRPI0711885A2 (fr)
CA (1) CA2650133A1 (fr)
CL (1) CL2007001542A1 (fr)
CR (1) CR10430A (fr)
DK (1) DK2044101T3 (fr)
EC (1) ECSP088922A (fr)
ES (1) ES2441993T3 (fr)
HR (1) HRP20140055T1 (fr)
IL (1) IL194880A (fr)
MA (1) MA30485B1 (fr)
MX (1) MX2008015216A (fr)
MY (1) MY146920A (fr)
NO (1) NO20085032L (fr)
NZ (1) NZ572154A (fr)
PE (2) PE20121011A1 (fr)
PL (1) PL2044101T3 (fr)
PT (1) PT2044101E (fr)
RU (1) RU2450015C2 (fr)
SI (1) SI2044101T1 (fr)
TN (1) TNSN08496A1 (fr)
TW (2) TWI342310B (fr)
UA (1) UA95627C2 (fr)
WO (1) WO2007142986A2 (fr)
ZA (1) ZA200808449B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060977A1 (es) * 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
WO2008082562A2 (fr) * 2006-12-20 2008-07-10 Novartis Ag Composés anti-bactériens et leurs procédés de fabrication
EP2170907A2 (fr) 2007-06-04 2010-04-07 Novartis Ag Macrocycles et leurs utilisations
MY156466A (en) * 2007-12-12 2016-02-26 Novartis Ag Aminothiazoles and their uses
AU2012261611B2 (en) * 2007-12-12 2014-05-15 Novartis Ag Aminothiazoles and their uses
WO2014167371A1 (fr) * 2013-04-12 2014-10-16 Naicons S.C.A.R.L. Analogues de l'antibiotique aminothiazole ge2270
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN113219078B (zh) * 2021-03-25 2022-12-16 广东产品质量监督检验研究院（国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室） 一种生活用纸制品中17种有机抗菌剂快速筛查方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) * 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
EP0406745B1 (fr) * 1989-07-04 1995-01-25 GRUPPO LEPETIT S.p.A. Antibiotique GE 22270, facteurs A1,A2,A3 et H
DE69108972T2 (de) * 1990-03-08 1995-10-19 Lepetit Spa Antibiotika GE 2270 Faktoren B1, B2, C1, D1, D2, E und T.
IL100572A (en) * 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DE69224497T2 (de) * 1991-08-30 1998-07-02 Biosearch Italia Spa Faktor C2a des Antibiotikums CE 2270
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2151616A1 (fr) 1992-12-22 1994-07-07 Sergio Stella Antibiotiques ge 37468 a, b et c
AU3805295A (en) 1994-11-08 1996-05-31 Gruppo Lepetit S.P.A. Microbial transformation process for obtaining antibiotic ge 2270 factor d2
CA2212372A1 (fr) * 1995-02-07 1996-08-15 Biosearch Italia S.P.A. Derives prolineamides basiques des antibiotiques ge 2270 et analogues
WO1996024608A1 (fr) * 1995-02-07 1996-08-15 Biosearch Italia S.P.A. Derives basiques oxazoline-amides des antibiotiques ge 2270 ou similaires
EP0880541B1 (fr) * 1996-02-14 2003-01-15 Biosearch Italia S.p.A. Derives des facteurs de l'antibiotique ge2270
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
BR0305070A (pt) * 2002-06-17 2004-09-21 Vicuron Pharm Inc Uso de derivado amida de ge 2270 fator a3 para tratamento da acne
AU2005327139A1 (en) 2004-09-22 2006-08-17 Merck & Co., Inc. Antibiotic compound
AR060977A1 (es) * 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
MY156466A (en) * 2007-12-12 2016-02-26 Novartis Ag Aminothiazoles and their uses

Also Published As

Publication number Publication date
EP2322536A3 (fr) 2011-11-30
TNSN08496A1 (en) 2010-04-14
AR060977A1 (es) 2008-07-23
TW201107337A (en) 2011-03-01
EP2044101A2 (fr) 2009-04-08
EP2322536A2 (fr) 2011-05-18
PE20121011A1 (es) 2012-08-25
CR10430A (es) 2009-01-15
MX2008015216A (es) 2008-12-12
DK2044101T3 (da) 2014-01-13
HK1127614A1 (en) 2009-10-02
ZA200808449B (en) 2014-12-23
MY146920A (en) 2012-10-15
PE20080103A1 (es) 2008-04-03
RU2450015C2 (ru) 2012-05-10
CA2650133A1 (fr) 2007-12-13
AU2007255025A1 (en) 2007-12-13
EP2044101B1 (fr) 2013-10-09
US7851439B2 (en) 2010-12-14
ES2441993T3 (es) 2014-02-07
WO2007142986A2 (fr) 2007-12-13
PL2044101T3 (pl) 2014-03-31
KR101061658B1 (ko) 2011-09-01
PT2044101E (pt) 2014-01-03
US20100267757A1 (en) 2010-10-21
UA95627C2 (ru) 2011-08-25
CN102399260B (zh) 2015-04-15
CN102399260A (zh) 2012-04-04
KR20090006869A (ko) 2009-01-15
US20080221142A1 (en) 2008-09-11
WO2007142986A3 (fr) 2008-04-10
CL2007001542A1 (es) 2008-03-14
NO20085032L (no) 2008-12-16
RU2008150785A (ru) 2010-07-10
HRP20140055T1 (hr) 2014-02-14
TWI342310B (en) 2011-05-21
JP2009538914A (ja) 2009-11-12
JP5351014B2 (ja) 2013-11-27
NZ572154A (en) 2011-12-22
SI2044101T1 (sl) 2014-01-31
IL194880A (en) 2015-02-26
TW200811189A (en) 2008-03-01
CN101454337A (zh) 2009-06-10
BRPI0711885A2 (pt) 2012-03-06
ECSP088922A (es) 2008-12-30
AU2007255025B2 (en) 2011-07-14
IL194880A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
MA31767B1 (fr) Composes organiques et leurs utilisations
MA30485B1 (fr) Aminothiazoles et leurs utilisations
MA33155B1 (fr) Composes organiques et leurs utilisations
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
HRP20040684B1 (hr) Spojevi 2,4-pirimidindiamina i njihova upotreba
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA200870019A1 (ru) Лактамовые соединения и способы их применения
MY147247A (en) Organic compounds and their uses
MA30340B1 (fr) Nouveaux composes
TW200612926A (en) Compounds and compositions as ppar modulators
TNSN05272A1 (fr) Ligands de recepteurs de cannabinoides et leurs utilisations
TNSN05317A1 (fr) Ligands des recepteurs de cannabinoides et leurs utilisations
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
MA27767A1 (fr) Ligands des recepteurs de cannabinoides et leurs utilisations
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
WO2005039504A3 (fr) Composes et methodes permettant de traiter les maladies et etats pathologiques lies au recepteur 2 de type toll
TW200509892A (en) Novel aminobenzophenone compounds
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
SE0302304D0 (sv) Novel compounds